About Us
NeuDirection Limited established in Oct. 2023. We are a spin-off company from RP3 of CRMH, HKISI, CAS.
Our focus is on the development of innovative small molecules and neuropeptide-based drugs, targeting unexplored GPCRs in the brain representing brand new mechanisms.
Our team has experienced professionals with deep expertise in pharmaceuticals, neuroscience, chemical synthesis, drug development and cell biology.
Four Pillars of
Drug Discovery
At NeuDirection, our approach to neurological drug discovery and development is built upon four fundamental pillars: People, Platform, Pipeline, and Translation. These pillars have been instrumental in successfully propelling new drugs to the IND (Investigational New Drug) stage.
People
Our international team of experts is our greatest asset, with a diverse range of specializations in pharmaceuticals, neuroscience, chemistry, and cell biology.
Platforms
We leverage cutting-edge platforms, including High-Throughput Screening (HTS) and advanced Pharmacology, to accelerate the discovery process.
Pipeline
We boast a robust portfolio of early and late-stage projects, focusing on developing innovative treatments for neurological disorders such as amblyopia, tinnitus, and epilepsy.
Translation
Our translational strategy is focused on maximizing impact through out-licensing, achieving significant milestones, and securing royalties.
Our Founders
Driving innovation and excellence, our team leaders bring unparalleled expertise and visionary leadership to NeuDirection’s mission of transforming neurological drug discovery and development.
